Skip to main content
OpenTrials
Completed

NCT Number: NCT03823274

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chungnam National University Hospital

Daejeon, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women over 60 years old at the time of written consent
  • Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg
  • Written informed consent voluntarily signed

Exclusion criteria

  • Those with evidence other brain lesions such as brain tumors
  • Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin
  • Contraindicate to Aspirin or Clopidogrel or allergic to the drug
  • Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage
  • Cancer disease that can shorten life expectancy
  • Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism
  • Subjects other than the above unsuitable for this clinical study identified by Investigator

Treatment and study plan

Aspirin, Clopidogrel

Drug

to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel

Primary outcomes

  1. evaluate the relationship of stroke recurrence and anti-platelet resitance

    Time frame: 12weeks

    To evaluate the relationship of stroke recurrence and anti-platelet resitance in ischemic stroke patients receiving aspirin 10mmg and clopidogrel 75mg for 12weeks

Sponsors and collaborators

Lead sponsor

Yuhan Corporation

Industry

Registry information

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jan 30, 2019
Registry last updated
Oct 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.